Hjem › Tumorer i hjerne og ryggmarg › California
Kliniske studier for Tumorer i hjerne og ryggmarg i California
13 studier for Tumorer i hjerne og ryggmarg søker deltakere på steder i California.
Byer i California
- Los Angeles6 studier
- Mountain View5 studier
- San Francisco4 studier
- Orange4 studier
- San Diego3 studier
- Baldwin Park3 studier
Offisiell studietekst (engelsk)
A Study of PHST001 in Advanced Solid Tumors
- Precision NextGen Oncology & Research Center, Beverly Hills
- USC Norris Comprehensive Cancer Center, Los Angeles
- Stanford University School of Medicine, Palo Alto
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT06840886Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
- UCSF Benioff Children's Hospital, San Francisco
RekruttererFase 1
24 Months – 18 Years · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06441331Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Precision NextGen Oncology, Beverly Hills
- OPN Healthcare, Inc, Glendale
- University of Southern California, Los Angeles
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 24. sep. 2026 · NCT06047379Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
- Cedars-Sinai Medical Center, Los Angeles
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 21. sep. 2026 · NCT04977375PilotStudyAssessSafeActiveSurveillancApproachLocalThe Pa w/BrainMetsUndergoinCNSPenetratSystemicThe
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 18. sep. 2026 · NCT07827001A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors
- Children's Hospital Orange County (CHOC), Orange
RekruttererFase 1
Alder 5 til 18 · Alle kjønn · Oppdatert 15. sep. 2026 · NCT06357377Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- Providence Medical Foundation, Fullerton
- California Research Institute, Los Angeles
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2026 · NCT05386108Project: Every Child for Younger Patients With Cancer
- Kaiser Permanente Downey Medical Center, Downey
- City of Hope Comprehensive Cancer Center, Duarte
- Loma Linda University Medical Center, Loma Linda
- og 15 flere
RekruttererObservasjonsstudie
Opp til 25 år · Alle kjønn · Oppdatert 25. aug. 2026 · NCT02402244Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).
- Children's Hospital Los Angeles, Los Angeles
RekruttererFase 2
Alder 1 til 26 · Alle kjønn · Oppdatert 4. aug. 2026 · NCT07680439DALY II USA/ MB-CART2019.1 for DLBCL
- UC San Diego Health, La Jolla
- Stanford University, Stanford
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 13. jul. 2026 · NCT04792489ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
- University of California, San Francisco, San Francisco
RekruttererFase 1
Alder 2 til 21 · Alle kjønn · Oppdatert 11. jun. 2026 · NCT04732065SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Duarte
- Massive Bio SYNERGY-AI site, Irvine
- Massive Bio SYNERGY-AI site, La Jolla
- og 3 flere
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774Prospective Data Registry and Quality of Life Assessment of Patients Undergoing Radiotherapy With the RefleXion Medical Radiotherapy System
- City Of Hope, Duarte
- Stanford Cancer Center, Palo Alto
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 15. aug. 2025 · NCT05406167Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.